NCT04283669 2026-03-13
NF110
University of Alabama at Birmingham
Phase 2 Completed
Clinical Trials
11 trialsNCT07420751 2026-02-20
Assessment of Patient Experience With Auto-Captioning Glasses in NF2-Related-Schwannomatosis
Massachusetts General Hospital
Phase NA Recruiting
NCT07131722 2026-01-23
Study to Determine Optimal Dose, Evaluate the Efficacy and Safety of PRG-N-01 in Patients With Neurofibromatosis Type II
PRG Science & Technology Co., Ltd.
Phase 1/2 Not yet recruiting
NCT04374305 2026-01-12
INTUITT-NF2
Massachusetts General Hospital
Phase 2 Active not recruiting
NCT03406208 2025-12-24
Resiliency Training for Adults With Neurofibromatosis Via Live Videoconferencing
Massachusetts General Hospital
Phase NA Completed
NCT03079999 2025-12-18
Study of Aspirin in Patients With Vestibular Schwannoma
Massachusetts Eye and Ear Infirmary
Phase 2 Active not recruiting
NCT05521048 2025-12-08
Doxycycline in Cutaneous Schwannoma (NF2)
Massachusetts Eye and Ear Infirmary
Phase 1/2 Active not recruiting
NCT02282917 2025-12-05
Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma
Massachusetts Eye and Ear Infirmary
Phase EARLY_PHASE1 Terminated
NCT01552434 2025-10-14
Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT05130866 2025-10-07
POPLAR-NF2
Recursion Pharmaceuticals Inc.
Phase 2/3 Terminated
NCT03095248 2025-04-22
SEL-TH-1601
Children's Hospital Medical Center, Cincinnati
Phase 2 Terminated